LM-101 injection study for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and willing to sign consent before any study steps
- Your cancer is an advanced solid tumor that has returned or keeps growing after standard treatment
- You have at least one measurable tumor spot the doctors can track on scans
- You can do daily activities fairly well (ECOG 0–1) and are expected to live at least 3 months
- Your recent labs show your organs and bone marrow can handle treatment (checked within 7 days before the first dose)
- If you join the combination part, you must provide stored or fresh tumor tissue for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new drug called LM-299 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if LM-299 is safe and effective.
This trial tests a new drug called LM-364, either by itself or combined with other anti-cancer treatments. The goal is to see if it can help people with advanced solid tumors that have not responded to standard therapies.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
Hear when a new Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.